Studying the effect of Rivaroxaban 2.5 mg daily on Arteriovenous hemodialysis graft maintenance and thrombosis

Phase 3

• Conditions: Artificial vein thrombosis in dialysis patients.; Thrombosis of cardiac prosthetic devices, implants and grafts, initial encounter; T82.867A

• Registration Number: IRCT20231108059994N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

Dependence on hemodialysis or the need for hemodialysis in the near future
Installing a new artificial vein for dialysis

Exclusion Criteria

Recent major bleeding (within the last 6 months) that is defined as follows: bleeding requiring transfusion, bleeding in a high-risk area (retroperitoneal or intracranial), bleeding that caused a decrease in body volume or hospitalization, or bleeding that caused Hg drop is more than 2 gr/dl.
Inability to take oral medication
Anticoagulant use for another reason
Life expectancy of less than two months or waiting for recovery of renal failureOpen in

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Thrombosis rate of artificial vein in one, three and six months after implantation of artificial dialysis vessel. Timepoint: in one, three and six months after implantation of artificial dialysis vessel. Method of measurement: Occurrence of thrombosis in an artificial vessel.